ASTELLAS PHARMA US, INC

Lobbying client · Illinois · filed 2025 to 2026

Pharmaceutical research and manufacturing company.

$6,740,000 Reported spend

42 Filings counted

5 Outside firms hired

8 Bills named

Spend is reported income plus in-house expenses across 42 filings. 1 further filing for this client was restated by a later amendment and is left out of every total here. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 6 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well. These filings have also been reported as ASTELLAS PHARMA US, ASTELLAS PHARMA US, INC.

Who filed for this client 6

ASTELLAS PHARMA US, INC. $4,640,000 In-house, the client's own filings · 7 filings
TARPLIN, DOWNS & YOUNG, LLC $560,000 Outside firm · 7 filings
THEGROUP DC, LLC $490,000 Outside firm · 7 filings
TIBER CREEK GROUP $420,000 Outside firm · 7 filings
TODD STRATEGY GROUP $350,000 Outside firm · 7 filings
JEFFREY J. KIMBELL & ASSOCIATES, INC. $280,000 Outside firm · 7 filings

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

Bills named in these filings 8

H.R. 1300
PSA Screening for HIM Act

11 filings
S. 297
PSA Screening for HIM Act

6 filings
H.R. 946
ORPHAN Cures Act

2 filings
H. Res. 1090
Expressing support for the designation of February 2026 as "Low Vision and Vision Impairment Awareness Month".

2 filings
S. 1862
ORPHAN Cures Act

2 filings
H.R. 1
One Big Beautiful Bill Act

1 filing
H.R. 5376
Impacts and Outcomes for Health Career Training Act

1 filing
S. 392
Sloan Canyon Conservation and Lateral Pipeline Act

1 filing

Reported by year 2 years

2026 $2,480,000 18 filings
2025 $4,260,000 24 filings

Issues lobbied 6

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 4

HOUSE OF REPRESENTATIVES 42
SENATE 41
Centers For Medicare and Medicaid Services (CMS) 9
Natl Institutes of Health (NIH) 7

Recent filings 43 total

Q3 report

THEGROUP DC, LLC

3rd Quarter 2026 (July 1 - Sep 30) · House · $70,000 income · posted Oct 20, 2026

View → Q3 report

TODD STRATEGY GROUP

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2026

View → Q3 report

TARPLIN, DOWNS & YOUNG, LLC

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $80,000 income · posted Oct 20, 2026

View → Q3 report

ASTELLAS PHARMA US, INC.

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $480,000 expenses · posted Oct 20, 2026

View → Q3 report

TIBER CREEK GROUP

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $60,000 income · posted Oct 19, 2026

View → Q3 report

JEFFREY J. KIMBELL & ASSOCIATES, INC.

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $40,000 income · posted Oct 16, 2026

View → Q2 report

TARPLIN, DOWNS & YOUNG, LLC

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $80,000 income · posted Jul 20, 2026

View → Q2 report

TARPLIN, DOWNS & YOUNG, LLC Amended

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $80,000 income · posted Jul 20, 2026

View → Q2 report

TODD STRATEGY GROUP

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 20, 2026

View → Q2 report

ASTELLAS PHARMA US, INC.

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $510,000 expenses · posted Jul 20, 2026

View → Q2 report

JEFFREY J. KIMBELL & ASSOCIATES, INC.

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $40,000 income · posted Jul 20, 2026

View → Q2 report

THEGROUP DC, LLC

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $70,000 income · posted Jul 20, 2026

View → Q2 report

TIBER CREEK GROUP

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 18, 2026

View → Q1 report

THEGROUP DC, LLC

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $70,000 income · posted Apr 20, 2026

View → Q1 report

TIBER CREEK GROUP

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $60,000 income · posted Apr 20, 2026

View → Q1 report

ASTELLAS PHARMA US, INC.

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $590,000 expenses · posted Apr 20, 2026

View → Q1 report

TODD STRATEGY GROUP

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $50,000 income · posted Apr 20, 2026

View → Q1 report

TARPLIN, DOWNS & YOUNG, LLC

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $80,000 income · posted Apr 20, 2026

View → Q1 report

JEFFREY J. KIMBELL & ASSOCIATES, INC.

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $40,000 income · posted Apr 20, 2026

View → Q4 report

THEGROUP DC, LLC

4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $70,000 income · posted Jan 20, 2026

View →

Showing the 20 most recent of 43 filings. Search the explorer for "ASTELLAS PHARMA US, INC".

Keep going

Filings through October 20, 2026, the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.